TRB Trademark

Trademark Overview


On Wednesday, March 11, 2020, a trademark application was filed for TRB with the United States Patent and Trademark Office. The USPTO has given the TRB trademark a serial number of 79284012. The federal status of this trademark filing is REGISTERED as of Tuesday, February 2, 2021. This trademark is owned by TRB CHEMEDICA INTERNATIONAL SA. The TRB trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceuticals, namely, anti-neurodegenerative, anti-neurotrophic, anti-antineurotoxic, neuroprotective and neurorestorative effect agents; pharmaceuticals, namely, immunopharmaceuticals; medical and veterinary preparations, namely, preparations for use in treating joint disease in horses, and antioxidants; pharmaceutical and medicinal preparations and substances for treating and preventing ophthalmic, ocular, neurological, metabolic, dermatological, arthritic, cognitive, or sexual dysfunction-related conditions, disorders or diseases; pharmaceutical and medicinal preparations and substances for treating and preventing joint, ligament, tendon, cartilage, bone, damaged skin or tissue-related conditions, disorders or diseases; pharmaceutical and medicinal preparations and substances for the treatment of central or peripheral nervous system-related, spinal cord-related, or early stages of traumatic or acute vascular injury-related disorders and diseases; pharmaceutical and medicinal prep...
trb

General Information


Serial Number79284012
Word MarkTRB
Filing DateWednesday, March 11, 2020
Status700 - REGISTERED
Status DateTuesday, February 2, 2021
Registration Number6258760
Registration DateTuesday, February 2, 2021
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, November 17, 2020

Trademark Statements


Description of MarkThe mark consists of a circular design outlined in blue containing zig-zag bands in blue followed to the right by the letters "TRB" in blue. The color white represents background, outlining, shading, and/or transparent areas and is not part of the mark.
Goods and Servicespharmaceuticals, namely, anti-neurodegenerative, anti-neurotrophic, anti-antineurotoxic, neuroprotective and neurorestorative effect agents; pharmaceuticals, namely, immunopharmaceuticals; medical and veterinary preparations, namely, preparations for use in treating joint disease in horses, and antioxidants; pharmaceutical and medicinal preparations and substances for treating and preventing ophthalmic, ocular, neurological, metabolic, dermatological, arthritic, cognitive, or sexual dysfunction-related conditions, disorders or diseases; pharmaceutical and medicinal preparations and substances for treating and preventing joint, ligament, tendon, cartilage, bone, damaged skin or tissue-related conditions, disorders or diseases; pharmaceutical and medicinal preparations and substances for the treatment of central or peripheral nervous system-related, spinal cord-related, or early stages of traumatic or acute vascular injury-related disorders and diseases; pharmaceutical and medicinal preparations and substances for the treatment of pain, inflammation, physical lesions, and wounds; analgesics; anti-inflammatories; medicines for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; medicines for use as surgical aid during cataract surgery procedures; medicines for the treatment of osteoarthritis and rheumatoid arthritis; medicines for the prevention of osteoporosis; medicines for the treatment of musculo-skeletal conditions, disorders or diseases; medicines for the treatment of tendinopathy; medicines for joint recovery after arthroscopy; medicines to help assist with the regeneration of ligament and tendon fibers; medicines for the treatment of immune system related diseases and disorders; medicines for the treatment of blepharitis, glaucoma, and degenerative eye pathologies; pharmaceutical drugs for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; pharmaceutical drugs for use as surgical aid during cataract surgery procedures; pharmaceutical drugs for the treatment of osteoarthritis and rheumatoid arthritis; pharmaceutical drugs for the prevention of osteoporosis; pharmaceutical drugs for the treatment of musculo-skeletal conditions, disorders or diseases; pharmaceutical drugs for the treatment of tendinopathy; pharmaceutical drugs for joint recovery after arthroscopy; pharmaceutical drugs to help assist with the regeneration of ligament and tendon fibers; pharmaceutical drugs for the treatment of immune system related diseases and disorders; pharmaceutical drugs for the treatment of blepharitis, glaucoma, and degenerative eye pathologies; therapeutic drugs for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; therapeutic drugs for use as surgical aid during cataract surgery procedures; therapeutic drugs for the treatment of osteoarthritis and rheumatoid arthritis; therapeutic drugs for the prevention of osteoporosis; therapeutic drugs for the treatment of musculo-skeletal conditions, disorders or diseases; therapeutic drugs for the treatment of tendinopathy; therapeutic drugs for joint recovery after arthroscopy; therapeutic drugs to help assist with the regeneration of ligament and tendon fibers; therapeutic drugs for the treatment of immune system related diseases and disorders, and therapeutic agents for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; therapeutic agents for use as surgical aid during cataract surgery procedures; therapeutic agents for the treatment of osteoarthritis and rheumatoid arthritis; therapeutic agents for the prevention of osteoporosis; therapeutic agents for the treatment of musculo-skeletal conditions, disorders or diseases; therapeutic agents for the treatment of tendinopathy; therapeutic agents for joint recovery after arthroscopy; therapeutic agents to help assist with the regeneration of ligament and tendon fibers; therapeutic agents for the treatment of immune system related diseases and disorders; transdermal patches featuring vitamins for increasing energy for medical use; biological cartilage, bone or skin tissue intended for subsequent implantation; biological preparations for medical or veterinary use, namely, for the treatment of infectious diseases; sanitary preparations for medical purposes; dietetic food and substances in the nature of food supplements and vitamins supplements all adapted for medical or veterinary use; food for babies; dietary supplements for humans and animals; meal replacements, namely, meal replacement bars adapted for medical use and meal replacement beverages adapted for medical use, and dietetic beverages adapted for medical and veterinary use; materials for dressings, namely, dressings for wounds, burns or surgery, adhesive bandages, gauze for dressings, pledgets; disinfectants
Indication of Colors claimedThe color(s) blue is/are claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 27, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTRB CHEMEDICA INTERNATIONAL SA
Party Type30 - Original Registrant
Legal Entity Type33 - NOT AVAILABLE
AddressCH

Party NameTRB CHEMEDICA INTERNATIONAL SA
Party Type20 - Owner at Publication
Legal Entity Type33 - NOT AVAILABLE
AddressCH

Party NameTRB CHEMEDICA INTERNATIONAL SA
Party Type10 - Original Applicant
Legal Entity Type33 - NOT AVAILABLE
AddressCH

Trademark Events


Event DateEvent Description
Monday, April 27, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 23, 2020SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, May 1, 2020APPLICATION FILING RECEIPT MAILED
Wednesday, October 7, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 21, 2020ASSIGNED TO EXAMINER
Thursday, May 28, 2020NON-FINAL ACTION WRITTEN
Friday, May 29, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, June 30, 2020REFUSAL PROCESSED BY MPU
Tuesday, June 30, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, July 18, 2020REFUSAL PROCESSED BY IB
Wednesday, October 7, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 8, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, October 13, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 28, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 17, 2020PUBLISHED FOR OPPOSITION
Tuesday, November 17, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, May 5, 2021FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, February 2, 2021REGISTERED-PRINCIPAL REGISTER
Sunday, May 2, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, May 5, 2021FINAL DISPOSITION PROCESSED
Tuesday, May 18, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, May 18, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 18, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sunday, May 30, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Sunday, February 26, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sunday, February 26, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sunday, February 26, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sunday, June 30, 2024CORRECTION TRANSACTION RECEIVED FROM IB
Wednesday, September 18, 2024CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Sunday, June 9, 2024CHANGE OF NAME/ADDRESS REC'D FROM IB